Related references
Note: Only part of the references are listed.Anti-PD-1 therapy combined with chemotherapy in patients with advanced pancreas cancer in a real-world clinical setting.
Danyang Sun et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
Glen J. Weiss et al.
INVESTIGATIONAL NEW DRUGS (2018)
Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta-analysis
Shu-Hua Zhang et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer
Stijn van Roessel et al.
JAMA SURGERY (2018)
A phase II pilot trial of nivolumab (N) plus albumin bound paclitaxel (AP) plus paricalcitol (P) plus cisplatin (C) plus gemcitabine (G) (NAPPCG) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC).
Erkut Hasan Borazanci et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The Canadian Cancer Trials Group PA. 7 trial: Results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
Daniel John Renouf et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors
Hatem H. Soliman
ONCOTARGETS AND THERAPY (2017)
Hypermutation In Pancreatic Cancer
Jeremy L. Humphris et al.
GASTROENTEROLOGY (2017)
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
Christopher R. Heery et al.
LANCET ONCOLOGY (2017)
Combination cancer immunotherapies tailored to the tumour microenvironment
Mark J. Smyth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Rafael Winograd et al.
CANCER IMMUNOLOGY RESEARCH (2015)
PHASE I STUDY OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC)
H. Hammers et al.
ANNALS OF ONCOLOGY (2014)
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
L. Bracci et al.
CELL DEATH AND DIFFERENTIATION (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Inflammatory networks and immune surveillance of pancreatic carcinoma
Robert H. Vonderheide et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Laurence Zitvogel et al.
IMMUNITY (2013)
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
Hideki Ueno et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0
Alice P. Chen et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
The secret ally: immunostimulation by anticancer drugs
Lorenzo Galluzzi et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Richard E. Royal et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)
Mariacristina Di Marco et al.
ONCOLOGY REPORTS (2010)
Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
Sonja Gillen et al.
PLOS MEDICINE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
A Randomized Phase II Trial of Adjuvant Chemotherapy With Uracil/Tegafur and Gemcitabine Versus Gemcitabine Alone in Patients With Resected Pancreatic Cancer
Hideyuki Yoshitomi et al.
CANCER (2008)
Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas
JMD Plate et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: The TREND statement
DC Des Jarlais et al.
AMERICAN JOURNAL OF PUBLIC HEALTH (2004)
Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells
AK Nowak et al.
JOURNAL OF IMMUNOLOGY (2003)
Share Paper
